

Intratumoral plasmid IL-12 electroporation therapy in advanced melanoma patients induces systemic and intratumoral T cell responses.

T cell responses induced by plasmid IL-12 electroporation

Samantha K. Greaney¹, Alain P. Algazi^{1,2}, Katy K. Tsai^{1,2}, Kathryn T. Takamura³, Lawrence Chen¹, Christopher G. Twitty³, Li Zhang², Alan Paciorek², Robert H. Pierce^{3,4}, Mai H. Le³, Adil I. Daud^{1,2}, Lawrence Fong^{1,2}

¹ Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA; ²Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco; ³OncoSec Medical Incorporated, San Diego, CA; ⁴University of Washington, Seattle, WA

Co-corresponding authors:

Lawrence Fong, University of California San Francisco, 513 Parnassus Avenue, Room HSE301A, Box 0519, San Francisco, CA 94143-0519. Email: lawrence.fong@ucsf.edu

Adil Daud, University of California San Francisco, 1600 Divisadero, A741 San Francisco, CA 94115. Email: adil.daud@ucsf.edu

Abstract

Whereas systemic IL-12 is associated with potentially life-threatening toxicity, intra-tumoral delivery of IL-12 through tavokinogene telseplasmid electroporation (tavo) is safe and can induce tumor regression at distant sites. The mechanism by which these responses are mediated is unknown, but is presumed to result from a cellular immune response. In a phase II clinical trial of tavo (NCT01502293), samples from 28 cutaneous melanoma patients with in-transit disease were assessed for immune responses induced with this treatment. Within the blood circulating immune cell population, we found that the frequencies of circulating PD-1+ CD4+ and CD8+ T cells declined with treatment. Circulating immune responses to gp100 were also detected following treatment as measured by IFN- γ ELISPOT. Patients with a greater antigen-specific circulating immune response also had higher numbers of CD8+ T cells within the tumor. Clinical response was also associated with increased intratumoral CD3+ T cells. Finally, intratumoral T cell clonality and convergence were increased after treatment, indicating a focusing of the TCR repertoire. These results indicated that local treatment with tavo can induce a systemic T cell response and recruit T cells to the tumor microenvironment.

Keywords: (5-10)

Interleukin-12, electrogene transfer, electroporation, immunotherapy, tumor infiltrating lymphocytes

Introduction

IL-12 is a pro-inflammatory cytokine that was first discovered in 1989 and induces the proliferation and activation of NK cells and cytotoxic T cells [1], enhancing their effector functions [2]. IL-12 represents an important link between innate and adaptive immunity, as IL-12 produced by antigen-presenting cells stimulates the release of IFN- γ from T and NK cells [3]. IL-12 is involved in the Th1 response, and induces IFN- γ production [4]. IL-12 is important in antitumor immunity [5,6,7], and T cells have are important in IL-12-mediated tumor suppression [8].

Several studies show that IL-12 has the potential to mediate tumor protection and tumor rejection in different mouse models[9]. Unfortunately, early clinical trials using recombinant human IL-12 (rhIL-12) were unsuccessful due to limited clinical activity and unacceptable toxicities[10,11,12], including liver function abnormalities and death [11,13]. In Bajetta et al., patients received rhIL-12 by subcutaneous injection and although 3/10 patients had regression in some tumors, progression at other sites was simultaneously observed. Additionally, after the first cycle of treatment patients failed to respond to the therapy and almost no increase in serum IL-12 was detected[10]. Atkins et al. found that of 12 melanoma patients who were given intravenous injection of rhIL-12, one patient had a complete response for 4 weeks[11].

Melanoma may be an ideal tumor type for gene therapy because cutaneous and subcutaneous lesions are easily accessible. There are over 50 clinical trials using electroporation for gene delivery[14], and electroporation is efficacious in the delivery of chemotherapy for metastatic melanoma[15,16]. Several studies show that intratumoral plasmid IL-12 electroporation therapy is successful in murine melanoma models[17,18] and that intratumoral injection of IL-12 plasmid electroporation works as well as IL-12 adenovirus without the systemic toxicity observed with viral therapy [19]. Direct injection of IL-12 plasmid alone into the tumor alone has limited clinical activity [19,20].

Intratumoral plasmid IL-12 electroporation (tavo) therapy is efficacious in a phase I study of metastatic melanoma[21,22]. This study reported objective clinical response, a tolerable adverse event profile, and increased lymphocyte infiltration into treated tumors. We conducted a phase II trial examining 3 different schedules of tavo administration; we report here on the intratumoral and peripheral immune responses of schedule A in which patients received IT-tavo-EP on days 1, 5, and 8 of each 90-day cycle with a maximum of

four cycles, 2-4 lesions treated, and at least 1 lesion left untreated for the duration of the study. In this phase II clinical trial, patients with cutaneous or subcutaneous melanoma were treated with intratumoral plasmid IL-12 electroporation therapy and we examined immunological responses and correlated these with clinical outcomes (NCT01502293).

Materials and Methods

Patients

Patients with pathologically documented melanoma that was AJCC stage IIIB, IIIC, or IVM1a were eligible for treatment on this study. Patients also had at least two cutaneous or subcutaneous lesions accessible for electroporation. Patients had an ECOG performance status of 0-2, were 18 or older, had creatinine < 2x the upper limit of normal, serum bilirubin within institutional normal limits, absolute neutrophil count > 1000/mm, and a platelet count > 100,000/mm within 4 weeks before starting the trial. Patients were allowed to have prior chemotherapy and immunotherapy but these must have been halted at least 4 weeks prior to electroporation treatment. Patients were allowed to have radiation therapy, but it must have been at least two weeks prior to study treatment, all signs of toxicity must have abated, and patients must have progressive disease if the lesions to be treated were within the radiation field. Patients with prior IL-12 therapy, significant active infection, pregnancy, electronic pacemakers or defibrillators, or a life expectancy less than six months were excluded from this study. The primary endpoint of this trial was best overall objective response rate by protocol-specific, modified "skin" RECIST.

The Institutional Review Boards of all participating institutions approved the study protocol, was registered as legislation requires, and performed in accordance with the U.S. Common Rule. All patients gave written informed consent prior to participation in the trial [NCT01502293].

Clinical Trial Design

The main objective of this clinical trial was to determine the distant response rate of melanoma patients treated with intratumoral plasmid IL-12 electroporation therapy. Secondary objectives were to determine the local response rate, duration of response, time to objective response, and safety of this therapy in melanoma

patients. The exploratory objective was to determine the immunological effects of tavo, which is the focus of this manuscript. Blood samples were obtained from patients on days 1, 39, 90, 180, 270, and 360, where day 1 was the first day of treatment. Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood samples, and cryopreserved by isolation and resuspension in media (45% RPMI 1640 media (BioWhittaker, Cat #12-702F), 45% human serum albumin (25%), 10% DMSO (Sigma-Aldrich Sigma, Cat #D2650). PBMCs were then stored in liquid nitrogen for batch analysis. In schedule A of this trial, patients received IT-tavo-EP on days 1, 5, and 8 of each 90-day cycle with a maximum of four cycles, with 2 to 4 lesions treated, and at least 1 lesion left untreated for the duration of the study. Samples from a total of 28 patients accrued to the schedule A were available for these analyses. PBMCs were collected from whole blood samples and stored in liquid nitrogen. Tumor biopsies were formalin-fixed, paraffin embedded, cut into 5 μ m sections, and stored at room temperature.

Treatment

Patients were treated on an 8-day treatment cycle. 2-4 accessible superficial (cutaneous or subcutaneous) lesions were injected with plasmid immediately followed by electroporation of the treated lesions on days 1, 5, and 8 of the treatment cycle. ± 1 day variation in treatment scheduling was allowed. The volume of all tumors to be electroporated was determined using the formula: $V = ab^2/2$, where (a) is the longest diameter and (b) is the diameter perpendicular to (a). The plasmid injection volume was calculated with the formula: $P = V/4$. Plasmid was reconstituted in sterile 0.9% saline and injected at a concentration of 0.5mg/mL, with a maximum of 1mL total given per day. Immediately after tumor injection, the tumor was administered 6 pulses of electricity at a field strength of 1300 V/cm with a pulse width of 100 μ s at 1s intervals, using a medpulsar electroporation device (Oncosec Medical Incorporated).

After 6 months if there was evidence of persistent disease, patients were eligible for a second cycle of treatment. If the patient had stable disease or better, up to two additional cycles were allowed.

Patient Assessment

A study-specific modified “skin” Response Evaluation Criteria in Solid Tumors (RECIST) criteria was used to measure response. All skin lesions measuring at least 3 mm in longest diameter by clinical examination were included in target measurements in addition to non-skin lesions measuring at least 10 mm in the long axis and nodal lesions measuring at least 15 mm in the short axis. New cutaneous lesions measuring at least 3 mm in the longest diameter were included in the net sum of diameters and the appearance of new lesions did not automatically constitute disease progression. Response confirmation was not required and latent responses after disease progression were counted as responders.

ELISpot assays

We analyzed the antigen-specific T cell–response on days 1, 39, 90, 90, 180, and 360. Due to limitations in samples, we did not examine day 270. PBMCs were thawed and rested overnight in complete human media (RPMI-1640 with human serum AB, L-glutamine, Pen/Strep, sodium pyruvate, non-essential amino acids) at 37 °C 5% CO₂. The cells were then plated in triplicates of 3.0x10⁵ cells each and incubated with spanning peptide pools of 15-mers overlapping by 11 amino acids derived from gp100, NY-ESO-1, Mage-A3, or Melan-A/MART-1 (JPT Peptide Technologies) at 2 mcg/ml, leucoagglutinin PHA-L (Sigma, Cat# L2769) or without antigen in complete human media for 48 hours at 37°C in MultiScreen Filter Plates (Millipore, #S2EM004M99). Cells secreting IFN-γ were visualized by anti-human-IFN-γ enzyme-linked immunospot assay (ELISpot) (MABTECH, Cat #3420-2A). Plates were scanned with an automated ELISpot plate reader (CTL-ImmunoSpot Analyzer). Spots were counted using CTL Immunospot 5.0 Analyzer software. Final counts of antigen specific IFN-γ secreting cells were obtained by subtracting the number of spots counted in no-antigen control wells from test wells. Samples were accepted for inclusion in final analysis if positive control PHA wells had an average >100 spots/well, and negative control (no antigen) wells had <100 spots/well. The average number of activated cells in the negative control was 5.6, in positive controls 624.

Immunohistochemistry

Punch or fine needle aspirate (FNA) biopsies were taken up to two weeks before treatment, 11 days post-treatment, and 39 days post-treatment. One to two biopsies were taken and analyzed per patient at each

timepoint. 40 biopsies were analyzed; 3 were fine needle aspirates and 37 were core or punch biopsies. Biopsies were taken from treated and untreated tumors. Biopsies were formalin-fixed, paraffin embedded, and cut into 5µm sections. Sections were immunohistochemically stained for CD3 (Dako, Clone F7.2.38, Cat# M7254) and CD8 (Dako, Clone C8/144B, Cat# M7103) on the same section using the Envision G2 Doublestain System (Dako, Cat# K5361) according to the manufacturer's protocol. The entire slide was analyzed using an automated microscope scanner (Aperio Scanscope XT, Leica Biosystems) at 20X magnification. Positive cells were counted using AxioVision software (Zeiss), and analyzed as a percentage of all nucleated cells.

Flow Cytometry

Blood samples were obtained from patients on days 1, 39, and 90 of treatment for analysis of immune cell subsets by flow cytometry. An insufficient number of samples were available from the day 180, 270, and 360 timepoints to be analyzed. Frozen PBMC samples were thawed, washed twice with FACS buffer (PBS with 2% FBS and 2 mmol/L EDTA), and stained for surface cell markers with antibodies diluted in FACS buffer for 30 minutes at 4°C. Cells were then washed twice with FACS buffer. Intracellular staining was done using the FoxP3 fix/perm buffer set (Biolegend, Cat# 421403) according to the manufacturer's protocol. Intracellular stains for FoxP3 and Ki67 were done for 30 minutes at room temperature.

Effector CD4 T cells (CD4 Teff) were defined as CD3+CD4+FoxP3-; CD8 T cells were defined as CD3+CD4-; regulatory T cells (Tregs) were defined as CD3+CD4+FoxP3+CD127-; PD-1+ CD4 Teff cells were defined as CD3+CD4+FoxP3-PD-1+; PD-1+Ki67+ CD4 Teff cells were defined as CD3+CD4+FoxP3-PD-1+Ki67+; PD-1+Ki67- CD4 Teff cells were defined as CD3+CD4+FoxP3-PD-1+Ki67-; PD-1+ CD8 T cells were defined as CD3+CD4-PD-1+; PD-1+Ki67+ CD8 T cells were defined as CD3+CD4-PD-1+Ki67+; PD-1+Ki67- CD8 T cells were defined as CD3+CD4-PD-1+Ki67-. The gating strategy is shown in Supplemental Fig. S1. The antibodies used are listed in Supplemental Table S1.

TCRβ amplification and sequencing, clonotype identification and counting

The amplification and sequencing of TCRβ repertoire from RNA of FFPE tissue and PBMC, read mapping to clonotypes via identification of V and J segments, and counting of the number of unique clonotypes utilizing

the same methodology and analytical methods as has been previously described in detail[23]. Of note, after filtering for read quality, reads were mapped to a clonotype if at least 2 identical reads were found in a given sample. Clonotype frequencies were calculated as the number of sequencing reads for each clonotype divided by the total number of passed reads in each sample.

TCR sequencing data analysis was done by using TCR3D R package[24]. Clonality was calculated to measure the diversity of the clonotype population for each patient at each time point. Convergent frequency was defined as the cumulative frequency of the clones that share a same amino acid with other clones and was calculated for each sample. In order to measure the commonality between TCR sequences, Morisita's distance, a distance measurement from 0 to 1, maximally dissimilar to minimally dissimilar respectively was applied to examine the dynamic change in TCR sequence frequency from pre-treatment to post-treatment.

Statistical Analysis

This report examined the biomarker cohort of the Phase 2 study, which focused on the exploratory endpoints of the clinical trial by examining the immunological responses of patients treated with tavo. Patients who had a complete response, partial response, or stable disease were considered responders (R). Patients who had progressive disease during treatment were considered non-responders (NR). All patients were included in the analysis, regardless of whether they completed the trial or adhered to all trial protocols. Patient characteristics were compared between responders and non-responders using the Wilcoxon rank sum test or Fisher's exact test. All the analyses were done by the statistical computing software R version 3.4.2 (<https://www.r-project.org>) and SAS software version 9.4. Statistical significance was declared by $p < 0.05$.

ELISpot responses were compared between baseline and day 39, 90, 180, or 360 using the Wilcoxon matched-pairs signed rank test. Tumor infiltrating CD3+ and CD3+CD8+ T cells as a percentage of total nucleated cells were compared between baseline and day 11 or day 39 using the Wilcoxon matched-pairs signed rank test. Tumor infiltrating CD3+ and CD3+CD8+ T cells were compared between clinical responders and non-responders at baseline, day 11, and day 39 using the Mann-Whitney U-test. CD3+ and CD3+CD8+ tumor infiltrating T cells were correlated with ELISpot responses at baseline and at day 39 using Spearman's rank correlation. Circulating immune cell subsets analyzed by flow cytometry were compared between baseline

and day 39 or 90, and between day 39 and day 90 using the Wilcoxon matched-pairs signed rank test. All the analyses were done by R and SAS. Statistical significance was $p < 0.05$.

Results

Patient Outcomes

Cutaneous melanoma patients with in-transit disease were enrolled in the biomarker cohort of the study receiving Schedule A (Supplemental Fig. S2). We assessed paired biopsy specimens and blood from 18 responding and 11 non-responding patients. Patients received between 1 and 4 intratumoral injections for the first 3 cycles. One patient received 5 cycles, 4 patients received 4 cycles, 3 received 3 cycles, 2 received 2 cycles, and the remainder received 1 cycle. One patient had 1 lesion injected, 8 patients had 2 lesions injected, 6 patients had 3 lesions injected, 10 patients had 4 lesions injected, and the remainder had 5 or more lesions injected.

Treatment modulated the frequency of circulating T cells

To examine whether this local treatment induces systemic immune effects, we assessed the frequency of different circulating lymphocytes by flow cytometry (Supplemental Fig. S1). Whereas the percentages of circulating CD4 T_H1 cells and CD4 T_H2 cells were not significantly changed after treatment (Fig. 1A, B), the frequency of PD-1⁺ CD4 T_H1 cells was significantly decreased 90 days after treatment ($p = 0.0027$, Fig. 1C). PD-1⁺Ki67⁺ CD4 T_H1 cells were decreased after treatment ($p = 0.0002$, Fig. 1D). CD8 T cells and PD-1⁺ CD8 T cells were also significantly decreased 90 days after treatment ($p = 0.0347$, $p = 0.0006$, Fig. 1E, F), and PD-1⁺Ki67⁺ CD8 T cells were decreased 39 and 90 days after treatment ($p = 0.0138$, $p = 0.0002$, Fig. 1G). There was no significant difference in the studied circulating lymphocyte types between responders and non-responders (Supplemental Fig. S3).

Treatment induced systemic antigen-specific immune responses

PBMC samples from 25 patients were evaluated by ELISpot assay to assess for antigen-specific T cell responses to shared melanoma antigens. Systemic IFN- γ responses to gp100 were significantly higher at 180

days after treatment compared to baseline ($p = 0.0313$), but not at 39 days, 90 days, or 360 days after treatment (Fig. 2A). At 180 days after treatment, only clinical responders remained on trial, therefore we were unable to test if this change from baseline was seen only among responders or among all patients. IFN- γ responses to NY-ESO-1, MAGE-A3, or Melan-A/MART-1 did not significantly change after treatment (Fig. 2B, C, D). One patient had a very high preexisting T cell response to MAGE-A3 and this patient had a complete clinical response with treatment. At 90 days post-treatment, IFN- γ responses to MAGE-A3 were significantly lower for responders compared to non-responders ($p = 0.0236$), but were not significantly different pretreatment or at 39, 180, or 360 days after treatment. IFN- γ responses to gp100, NY-ESO-1, and Melan-A/MART-1 were not significantly different between responders and non-responders pre- or post-treatment (Fig. 2E, F, G, H).

Treatment-induced intratumoral T cell responses

Where available, paired pretreatment and post-treatment (day 11 and 39) tumor samples were assessed for T cell infiltration by immunohistochemistry. In most patients, one biopsy was taken and analyzed per patient at each timepoint, but in some cases, a second biopsy may have been taken from an untreated lesion. For all evaluable patients, there was no significant change in tumor-infiltrating CD3+ and CD3+CD8+ T cells after treatment (Supplemental Fig. S4). The percentage of CD3+ tumor-infiltrating T cells was higher in responders than in non-responders at day 39 after treatment ($p = 0.0293$) (Fig. 3A). Change in CD3+CD8+ tumor infiltrating T cells showed a similar trend at 39 days post-treatment but was not statistically significant ($p = 0.0593$, Fig. 3B).

For all available patients, T cell tumor infiltration was correlated with circulating antigen-specific T cells. Post-treatment infiltration of tumor with CD3+CD8+ T cells correlated with circulating antigen-specific T cells as measured by ELISpot, but were not correlated pre-treatment (Fig. 4). CD3+ tumor infiltrating immune cells are also correlated poorly with ELISpot responses pre-treatment, but correlated well on day 39 after treatment (Supplemental Fig. S5). CD3+CD8+ tumor infiltrating immune cells pre-treatment were significantly correlated with NY-ESO-1 ELISpot responses 39 days post-treatment ($r=0.68$, $p=0.0406$) (Supplemental Table S2).

These results supported the notion that immune changes induced by plasmid IL-12 electroporation at a local site may modulate circulating immune cells and that those patients with a higher magnitude of responses possess higher frequency of T cells in the tumor microenvironment.

Intratumoral T Cell Repertoire Changed with Treatment

We performed TCR sequencing to determine whether tivo treatment altered the breadth of T cell specificities within the tumor microenvironment. We found that the clonality of post-treatment (week 4 or week 6) tumors trended higher than that of baseline samples ($p=0.088$), consistent with focusing of the intratumoral TCR repertoire (Fig. 5A). TCR convergence, as measured by the cumulative frequency of the clones that share identical amino acid sequences, was also higher in post-treatment (week 4 or week 6) samples compared to baseline samples ($p=0.019$) (Fig. 5B). This change supported the notion that these changes may be driven by responses to antigen. The Morisita's distance, a measure of change, between baseline and post-treatment (week 4 or week 6) was significantly lower than that between week 4 and week 6 (i.e. the two post-treatment time points) ($p=0.002$), indicating there are more changes in the TCR repertoire from baseline to any post-treatment time points (week 4 and week 6) compared to subsequent changes between post-treatment time points (week 4 and week 6) (Fig. 5C). Convergent frequency was highly correlated with clonality ($r=0.80$, $p<0.001$) (Fig. 5D). There was no observed difference in clonality between responders and non-responders. Finally, when we filtered on T cell clonotypes that were induced with treatment (i.e. undetectable at baseline and detectable post-treatment), we found that these clonotypes were detectable in the blood (Supplemental Fig. S6). There were clonotypes that were 1) induced in the blood with treatment, 2) present at baseline and lost in the blood, and 3) present at baseline and persisting in the blood through treatment. These different patterns reflected the different patterns of ELISPOT responses seen with the different antigens, although we were not able to link antigen specificity to specific clonotypes. In particular, there were induced tumor clonotypes that were circulating at baseline and transiently lost with treatment (Supplemental Fig. S6D). This specific pattern parallels the anti-specific T cell response to MageA3 seen in the responders (Fig. 2C,G).

Discussion

Intratumoral plasmid IL-12 electroporation therapy can induce systemic clinical responses in metastatic melanoma patients [21]. Here, we showed that this treatment modulated T cell responses systemically, including a reduction in circulating PD-1 expressing CD4 and CD8 T cells. This phenotype is thought to be associated with T cell exhaustion, but also can mark tumor specificity and recent activation[25,26]. These results could support the notion that intratumor IL-12 electroporation can alter immunosuppression sufficiently within the tumor microenvironment to impact circulating T cells, and may indicate homing of activated circulating T cells to the tumor [18]. This is supported by the observed decrease in total circulating CD8 T cells and Ki67+ PD-1 expressing T cells, as well as a trend toward increased CD3 and CD8 T cells in the tumor following treatment. This is also consistent with the observed loss of baseline circulating T cell clonotypes that were subsequently found in the tumor.

With regards to the shared antigen responses, T cell-responses to some of the antigens were present at baseline in some patients. The only significant change in response was to gp100, although these data were driven by the clinical responders since non-responders were not evaluable at this late timepoint. The only significant difference between responders and non-responders was the decline in MageA3 responses at day 39 in the former. These could represent the circulating T cell clonotypes seen by TCR sequencing that were lost in the blood but induced in the tumor. One patient had a very high pre-existing response to MAGE-A3 that was maintained after treatment, and this patient was one of the 5 complete clinical responders. Our finding that intratumoral CD3+ T cells were higher in patients who responded after treatment may indicate that this is an important aspect of the antitumor response. As expected with IL-12, these patients may have successfully primed tumor-reactive T cells. We also found a trend toward higher CD8+ T cells in patients who were responders compared to nonresponders, although this increase was not statistically significant. We found that the number of circulating antigen specific IFN- γ T cells correlated with the number of intratumoral CD8+ T cells and total T cells after treatment, but not before. This supports the notion that antigen specific T cells are being recruited into the tumor from circulation. This correlation was most significant for NY-ESO1, Melan-A/MART-1, and gp100 specific circulating T cells; we observed an increase in gp100 specific T cells after treatment but did not observe this for in NY-ESO or Melan-A/MART-1 specific T cells. Additionally, we observed a difference among MAGE-A3 specific T cells between responders and non-responders following treatment, but this was

the antigen with the weakest correlation to intratumoral T cells. This may have indicated that antigen specific T cells were being differentially recruited to the tumor, but that this alone may not have been sufficient for an improved clinical response. Consistent with this, we found that there were significant changes in the T cell clonotypes induced by treatment leading to a narrowing to the intratumoral repertoire post treatment. Treatment induced a significant increase in TCRs that shared amino acid identity despite having different nucleotide sequence (i.e. increased convergence), supporting the notion that antigen-specific responses were being induced.

Previously, Daud et al. found no correlation between clinical response and lymphocyte infiltration using the same treatment [21]. This discrepancy may be due to the fact that that study did not look at specific T cell subsets within the tumor, did not use image analysis to quantify infiltration, and/or may simply be due to the smaller sample size in the prior study. Cha et. al found that there was an increase in MAGE-A3 and MART-1 specific IFN- γ producing T cells at 4 weeks after the same treatment [22]. In contrast, we did not observe an increase in T cells specific for these antigens, but we saw an increase in gp100 antigen specific T cells.

Limitations in our study included the small sample size, especially with availability of clinical samples at later timepoints. Additionally, this study accrued patients with treatable lesions including in transit disease, which may have a different immunobiology from melanoma metastatic to other sites. We were also evaluated a limited number of tumor samples, and were unable to compare differences between treated and untreated tumors. Future studies would benefit from the ability to evaluate treated and untreated lesions over time in more patients and assess the functional status and specificity of these intratumoral T cells.

The capacity of tavo to affect both the local and systemic immune responses makes combination therapy with other immune therapies such as immune checkpoint inhibitors a straightforward way to potentially improve its efficacy. There is a current trial underway (NCT02493361) in metastatic melanoma patients with low TILs combining anti-PD-1 (pembrolizumab) with tavo. The fact that we observed some increase in TILs and changes in the systemic immune response implied that this therapy has systemic effects. The results of this combination study will show if tavo is indeed helpful in priming an immune response that can then be enhanced by checkpoint blockade therapy.

Acknowledgements

Funding

This work was supported by grant funding from Oncosec to AA, AD, and LF.

Disclosure of Interest

KTT, CT, RHP, and MHL are current or former employees of and have ownership interest in Oncosec. AA and AD have ownership interest in and have received funding from Oncosec. LF has received research funding from Oncosec, Abbvie, Bavarian Nordic, BMS, Dendreon, Janssen, Merck and Roche/Genentech.

References

1. Kobayashi BYM, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, Loudon R, Sherman F, Perussia B, Trinchieri G. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. *J Exp Med* 1989; 170:827–45.
2. Aste-Amezaga M, D'Andrea A, Kubin M, Trinchieri G. Cooperation of Natural Killer Cell Stimulatory Factor/Interleukin-12 with Other Stimuli in the Induction of Cytokines and Cytotoxic Cell-Associated Molecules in Human T and NK Cells. *Cell Immunol* 1994; 156:480–92.
3. Chan SH, Perussia B, Gupta JW, Kobayashi M, Pospíšil M, Young HA, Wolf SF, Young D, Clark SC, Trinchieri G. Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. *J Exp Med*. 1991 Apr 1;173(4):869-79.
4. Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, Murphy KM. Development of TH1 CD4 β T cells through IL-12 produced by Listeria-induced macrophages. *Science* 1993; 260: 547–549.
5. Airoidi I, Di Carlo E, Cocco C, Sorrentino C, Fais F, Cilli M, D'Antuono T, Colombo MP, Pistoia V. Lack of IL12 β 2 signaling predisposes to spontaneous autoimmunity and malignancy. *Blood* 2005; 106:3846–53.
6. Meeran SM, Mantena SK, Meleth S, Elmets C, Katiyar SK. Interleukin-12-deficient mice are at greater risk of UV radiation-induced skin tumors and malignant transformation of papillomas to carcinomas. *Mol Cancer Ther* 2006; 5:825–32.
7. Liu J, Xiang Z, Ma X. Role of IFN regulatory factor-1 and IL-12 in immunological resistance to pathogenesis of N-methyl-N-nitrosourea-induced T lymphoma. *J Immunol* 2004; 173:1184–93.
8. Takeda K, Seki S, Ogasawara K, Anzai R, Hashimoto W, Sugiura K, Takahashi M, Satoh M, Kumagai K. Liver NK1.1+ CD4+ alpha beta T cells activated by IL-12 as a major effector in inhibition of experimental tumor metastasis. *J Immunol* 1996; 156:3366–73.
9. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, Gately MK, Wolf SF, Schreiber RD, Storkus WJ. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. *J Immunol* 1994; 153:1697–706.
10. Bajetta E, Del Vecchio M, Mortarini R, Nadeau R, Rakhit A, Rimassa L, Fowst C, Borri A, Anichini A, Parmiani G. Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. *Clin Cancer Res* 1998; 4:75–85.

11. Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, Ritz J, Sandler AB, Edington HD, Garzone PD, et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. *Clin Cancer Res* 1997; 3:409–17.
12. Gollob JA, Mier JW, Veenstra K, McDermott DF, Clancy D, Clancy M, Atkins MB. Phase I Trial of Twice-Weekly Intravenous Interleukin 12 in Patients with Metastatic Renal Cell Cancer or Malignant Melanoma: Ability to Maintain IFN- γ Induction Is Associated with Clinical Response. *Clin Cancer Res* 2000; 6:1678–92.
13. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, Sosman JA, Dutcher JP, Vogelzang NJ, Ryan JL. Effects of Single-Dose Interleukin-12 Exposure on Interleukin-12 – Associated Toxicity and Interferon-g Production. *Blood* 1997; 90:2451–548.
14. Heller R, Heller LC. Gene electrotransfer clinical trials. *Adv Genet* 2015; 89:235–62.
15. Ricotti F, Giuliodori K, Cataldi I, Campanati A, Ganzetti G, Ricotti G, Offidani A. Electrochemotherapy: An effective local treatment of cutaneous and subcutaneous melanoma metastases. *Dermatol Ther* 2014; 27:148–52.
16. Heller R, Jaroszeski MJ, Reintgen DS, Puleo CA, DeConti RC, Gilbert RA, Glass LF. Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. *Cancer* 1998; 83:148–57.
17. Lucas ML, Heller R. IL-12 gene therapy using an electrically mediated nonviral approach reduces metastatic growth of melanoma. *DNA Cell Biol* 2003; 22:755–63.
18. Lucas M, Heller LC, Coppola D, Heller R. IL-12 Plasmid Delivery by in Vivo Electroporation for the Successful Treatment of Established Subcutaneous B16.F10 Melanoma. *Mol Ther* 2002; 5:668–75.
19. Lohr F, Lo DY, Zaharoff DA, Hu K, Zhang X, Li Y, Zhao Y, Dewhirst MW, Yuan F, Li CY. Effective tumor therapy with plasmid-encoded cytokines combined with in vivo electroporation. *Cancer Res* 2001; 61:3281–4.
20. Mahvi D, Henry M, Albertini M, Weber S, Meredith K, Schalch H, Rakhmilevich A, Hank J, Sondel P. Intratumoral injection of IL-12 plasmid DNA - Results of a phase I/IB clinical trial. *Cancer Gene Ther* 2007; 14:717–23.

21. Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL, et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. *J Clin Oncol* 2008; 26:5896–903.
22. Cha E, Daud A. Plasmid IL-12 electroporation in melanoma. *Hum Vaccines Immunother* 2012; 8:1734–8.
23. Cha E, Klinger M, Hou Y, Cummings C, Ribas A, Faham M, Fong L. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. *Sci Transl Med*. 2014 May 28;6(238):238ra70.
24. Zhang L, Cham J, Paciorek A, Trager J, Sheikh N, Fong L. 3D: diversity, dynamics, differential testing - a proposed pipeline for analysis of next-generation sequencing T cell repertoire data. *BMC Bioinformatics*. 2017 Feb 27;18(1):129.
25. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. *Nature* 2006; 439:682–7.
26. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA, Chen L, Greenwald R, Freeman G, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. *Blood* 2009; 114:1537–44.

FIGURE LEGENDS

Figure 1. Modulation of circulating T cells with tavo treatment. Frequencies of circulating immune cell subsets were assessed on serial peripheral blood mononuclear cells by flow cytometry. (A) CD4 Teff, (B) Tregs, (C) PD-1+ CD4 Teff, (D) PD-1+Ki67+ CD4 Teff cells, (E) CD8 T cells, (F) PD-1+ CD8 T cells, (G) PD-1+Ki67+ CD8 T cells were gated and expressed as a percentage of total lymphocytes (n = 20). (Wilcoxon matched pairs test.)

Figure 2. Antigen-specific T cells responses following tavo therapy in melanoma patients. IFN- γ response of circulating peripheral blood mononuclear cells (PBMCs) were measured by enzyme linked immunospot (ELISpot). Specificity to (A) gp100, (B) NY-ESO, (C) MAGE-A3, and (D) Melan-A/MART-1 were tested pre- and post-treatment in response to the respective peptide pools. Each line represents a single subject (n = 24). (Wilcoxon matched pairs test.) Antigen-specific T cells responses following tavo therapy between clinical responders and non-responders, with specificity to (E) gp100, (F) NY-ESO, (G) MAGE-A3, and (H) Melan-A/MART-1 (n = 24). Lines indicate median \pm interquartile range. (Significance measured by Mann-Whitney U test.)

Figure 3. T cell infiltration post-treatment. Comparison of (A) CD3+ and (B) CD3+CD8+ tumor infiltrating lymphocytes between clinical responders (R) and non-responders (NR) pre-treatment, 11 days after treatment, and 39 days after treatment. Each dot represents a single subject (n = 19). Treated lesions are denoted with filled circles while untreated lesions are denoted with open circles. Lines indicate median \pm interquartile range. (Significance measured by Mann-Whitney U test.)

Figure 4. Association between intratumoral T cell infiltration and circulating immune responses. Correlation of CD3+CD8+ tumor infiltrating lymphocytes with antigen specific IFN- γ T cell responses before treatment with plasmid IL-12 electroporation (A, C, E, G), and 39 days after treatment (B, D, F, H) for all patients. Responders are denoted by filled circles while non-responders are denoted by open circles (n = 12). Best-fit lines are overlaid on the graphs. (P- and r-values were determined by Spearman's rank correlation).

Figure 5. Diversity and dynamics of TCR repertoire in tumors. T cell receptor sequencing was performed on tumor biopsies prior to or following treatment (n = 9). **(A)** Clonality of biopsy samples obtained pre- and post-treatment samples was assessed (p=0.088). **(B)** Convergent frequency of pre- and post-treatment samples were also assessed (p=0.019). **(C)** Morisita's distance was calculated between baseline and post-treatment timepoints. Boxplots indicate median \pm interquartile range, lines represent standard error. (Significance measured by Wilcoxon matched pairs test) **(D)** The correlation between convergent frequency and clonality was assessed (r=0.80, p<0.001) (line fitted by a linear regression model).

Figure 1.




Figure 2.




Figure 3.




Figure 4.





Figure 5.



Cancer Immunology Research

Intratumoral plasmid IL-12 electroporation therapy in advanced melanoma patients induces systemic and intratumoral T cell responses

Samantha K. Greaney, Alain P Algazi, Katy K Tsai, et al.

Cancer Immunol Res Published OnlineFirst December 18, 2019.

Updated version	Access the most recent version of this article at: doi: 10.1158/2326-6066.CIR-19-0359
Supplementary Material	Access the most recent supplemental material at: http://cancerimmunolres.aacrjournals.org/content/suppl/2019/12/18/2326-6066.CIR-19-0359.DC1
Author Manuscript	Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts	Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org .
Permissions	To request permission to re-use all or part of this article, use this link http://cancerimmunolres.aacrjournals.org/content/early/2019/12/18/2326-6066.CIR-19-0359 . Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.